Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Curis from a "sell" rating to a "hold" rating in a research report on Thursday, May 12th.
Curis Stock Performance
Shares of CRIS Stock traded up $0.08 during mid-day trading on Friday, hitting $1.15. The company's stock had a trading volume of 1,275,657 shares, compared to its average volume of 1,678,774. The stock has a market cap of $105.39 million, a price-to-earnings ratio of -1.85 and a beta of 2.66. Curis has a 52-week low of $0.70 and a 52-week high of $9.04. The business has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.71.
Curis (NASDAQ:CRIS - Get Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.17). Curis had a negative return on equity of 68.41% and a negative net margin of 533.89%. During the same period last year, the business posted ($0.12) earnings per share. Equities research analysts predict that Curis will post -0.69 EPS for the current fiscal year.